Company news

Allogene Therapeutics, Inc. news in 2026

Allogene Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Allogene Therapeutics Reports Third Quarter 2026 Financial Results and Business Update

November 5, 2026

Allogene Highlights Clinical Progress and Next-Generation Innovation Across Its Off-the-Shelf CAR T Platform at SITC Annual Meeting

November 3, 2026

Allogene Therapeutics Announces November Investor Events Highlighting Q3 Results and Initial ALLO-329 Autoimmune Clinical Data

October 29, 2026

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

October 26, 2026

Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker

September 2, 2026

Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update

August 12, 2026

Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update

August 4, 2026

Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma

July 29, 2026

Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors

July 15, 2026

Allogene Therapeutics Announces Planned CEO Succession

May 28, 2026

Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update

May 13, 2026

Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia

April 21, 2026

Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026

April 20, 2026

Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock

April 15, 2026

Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases

April 14, 2026

Allogene Therapeutics Announces Pricing of Public Offering of Common Stock

April 13, 2026

Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL

April 12, 2026

Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock

April 12, 2026

Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026

April 10, 2026

Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update

March 12, 2026

Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update

March 11, 2026

Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update

March 2, 2026

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

February 5, 2026

Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T

January 8, 2026

Calls in 2026

Decks in 2026